Xylazine is a non-opioid agent linked to a growing number of overdose deaths across the country. As a non-opioid, the drug poses a threat to humans, in part because it does not respond to typical revival methods like Narcan.
The first panel will feature experts from across the country to discuss the impact of this epidemic on health careNASHVILLE, Tenn. (BUSINESS WIRE) Aegis Sciences Corporation is launching a key opinion leadership series titled “InPractice: Clinical Insights,” on July 26. The panel will feature health care experts f.
Testing should not be viewed as punitive, but instead as a necessary tool within the scope of medical practice to aid risk mitigation strategies and to help provide lifesaving treatment.